The Behavioral and Neuroinflammatory Impact of Ketamine in a Murine Model of Depression and Liver Damage.
Mădălina Iuliana Mușat, Ana-Maria Ifrim-Predoi, Smaranda Ioana Mitran, Eugen Osiac, Bogdan Cătălin
International journal of molecular sciences April 10, 2025 DOI: 10.3390/ijms26083558 via PubMed
Summary
AI-generated from the abstractKetamine relieved anhedonia and anxiety-like behavior in mice with both depression and non-alcoholic fatty liver disease (NAFLD), regardless of liver damage. It improved sociability, especially in older mice, but did not improve memory in those with liver injury. Acute ketamine did not worsen liver damage but appeared to affect brain cell changes (astrogliosis and neuronal loss). The findings suggest ketamine's antidepressant effects persist even with liver disease, though responses vary by age.
Study at a glance
| Characteristics | Animal model study Peer reviewed |
|---|---|
| Population | Young and aged male C57BL/6N mice |
| Intervention | Ketamine |
| Dose | 50 mg/kg |
| Topics | Depression Ketamine |
| Keywords | Cums Mcd diet Nafld Depression-treatment Liver-disease |
| Citations | 5 |
| Key finding | Ketamine relieved anhedonia and anxiety-like behavior in mice with NAFLD and depression, improved sociability in aged subjects, and did not worsen liver injury. |
Abstract
Non-alcoholic fatty liver disease (NAFLD) has been associated with depression and inadequate response to antidepressants. While ketamine has demonstrated efficacy in treating depression, its impact on pre-existing liver injury and depression remains unclear. This study aimed to evaluate the effects of ketamine treatment in a murine model of depression and liver damage, considering age-related differences. Young and aged male C57BL/6N mice were submitted to chronic unpredictable mild stress (CUMS) and methionine-choline-deficient (MCD) diet to induce depressive-like behavior and NAFLD. Behavioral testing (sucrose preference test, open field test, novel object recognition test, Crawley's sociability test) were used to assess ketamine's (50 mg/kg) effect on behavior. Hepatic ultrasonography was utilized to evaluate liver status. The cortical and hippocampal NeuN+, GFAP+, and Iba1+ signals were quantified for each animal. Ketamine administration proved effective in relieving anhedonia and anxiety-like behavior, regardless of liver damage. Although ketamine treatment did not improve memory in animals with liver damage, it enhanced sociability, particularly in aged subjects. The acute administration of ketamine did not affect the severity of liver injury, but seems to affect astrogliosis and neuronal loss. Although animal models of depression only replicate certain clinical features of the condition, they remain valuable for evaluating the complex and varied effects of ketamine. By applying such models, we could demonstrate ketamine's therapeutic versatility, and also indicate that responses to the treatment may differ across different age groups.